share_log

Acrivon Therapeutics | 8-K: Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

SEC announcement ·  May 14 20:04
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.